218 related articles for article (PubMed ID: 37747726)
1. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.
Huang Y; Durall RT; Luong NM; Hertzler HJ; Huang J; Gokhale PC; Leeper BA; Persky NS; Root DE; Anekal PV; Montero Llopis PDLM; David CN; Kutok JL; Raimondi A; Saluja K; Luo J; Zahnow CA; Adane B; Stegmaier K; Hawkins CE; Ponne C; Le Q; Shapiro GI; Lemieux ME; Eagen KP; French CA
Cancer Res; 2023 Dec; 83(23):3956-3973. PubMed ID: 37747726
[TBL] [Abstract][Full Text] [Related]
2. EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes.
Huang Y; Durall RT; Luong NM; Hertzler HJ; Huang J; Gokhale PC; Leeper BA; Persky NS; Root DE; Anekal PV; Montero Llopis PDLM; David CN; Kutok JL; Raimondi A; Saluja K; Luo J; Zahnow CA; Adane B; Stegmaier K; Hawkins CE; Ponne C; Le Q; Shapiro GI; Lemieux ME; Eagen KP; French CA
bioRxiv; 2023 Aug; ():. PubMed ID: 37645799
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors.
Ishi Y; Zhang Y; Zhang A; Sasaki T; Piunti A; Suri A; Watanabe J; Abe K; He X; Katagi H; Bhalla P; Natsumeda M; Zou L; Shilatifard A; Hashizume R
Mol Cancer Ther; 2022 May; 21(5):715-726. PubMed ID: 35247919
[TBL] [Abstract][Full Text] [Related]
4. The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.
Durall RT; Huang J; Wojenski L; Huang Y; Gokhale PC; Leeper BA; Nash JO; Ballester PL; Davidson S; Shlien A; Sotirakis E; Bertaux F; Dubus V; Luo J; Wu CJ; Keskin DB; Eagen KP; Shapiro GI; French CA
Cancer Res; 2023 Dec; 83(23):3846-3860. PubMed ID: 37819236
[TBL] [Abstract][Full Text] [Related]
5. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
[TBL] [Abstract][Full Text] [Related]
6. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
[TBL] [Abstract][Full Text] [Related]
7. Structural mechanism of BRD4-NUT and p300 bipartite interaction in propagating aberrant gene transcription in chromatin in NUT carcinoma.
Yu D; Liang Y; Kim C; Jaganathan A; Ji D; Han X; Yang X; Jia Y; Gu R; Wang C; Zhang Q; Cheung KL; Zhou MM; Zeng L
Nat Commun; 2023 Jan; 14(1):378. PubMed ID: 36690674
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Cooperativity as a Therapeutic Vulnerability in Cancer.
Kazansky Y; Kentsis A
Cancer Res; 2023 Dec; 83(23):3827-3829. PubMed ID: 38037453
[TBL] [Abstract][Full Text] [Related]
9. Supercharging BRD4 with NUT in carcinoma.
Eagen KP; French CA
Oncogene; 2021 Feb; 40(8):1396-1408. PubMed ID: 33452461
[TBL] [Abstract][Full Text] [Related]
10. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic analysis of the role of bromodomain-containing protein 4 (BRD4) in BRD4-NUT oncoprotein-induced transcriptional activation.
Wang R; You J
J Biol Chem; 2015 Jan; 290(5):2744-58. PubMed ID: 25512383
[TBL] [Abstract][Full Text] [Related]
12. Ectopic protein interactions within BRD4-chromatin complexes drive oncogenic megadomain formation in NUT midline carcinoma.
Alekseyenko AA; Walsh EM; Zee BM; Pakozdi T; Hsi P; Lemieux ME; Dal Cin P; Ince TA; Kharchenko PV; Kuroda MI; French CA
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4184-E4192. PubMed ID: 28484033
[TBL] [Abstract][Full Text] [Related]
13. BRD4 Regulates Transcription Factor ΔNp63α to Drive a Cancer Stem Cell Phenotype in Squamous Cell Carcinomas.
Fisher ML; Balinth S; Hwangbo Y; Wu C; Ballon C; Wilkinson JE; Goldberg GL; Mills AA
Cancer Res; 2021 Dec; 81(24):6246-6258. PubMed ID: 34697072
[TBL] [Abstract][Full Text] [Related]
14. EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway.
Zhang H; Zhu D; Zhang Z; Kaluz S; Yu B; Devi NS; Olson JJ; Van Meir EG
Oncogene; 2020 Jan; 39(5):1041-1048. PubMed ID: 31582835
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Ezh2 redistributes bivalent domains within transcriptional regulators associated with WNT and Hedgehog pathways in osteoblasts.
Carrasco ME; Thaler R; Nardocci G; Dudakovic A; van Wijnen AJ
J Biol Chem; 2023 Sep; 299(9):105155. PubMed ID: 37572850
[TBL] [Abstract][Full Text] [Related]
16. BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer.
Wu X; Liu D; Tao D; Xiang W; Xiao X; Wang M; Wang L; Luo G; Li Y; Zeng F; Jiang G
Mol Cancer Ther; 2016 May; 15(5):1029-42. PubMed ID: 26939702
[TBL] [Abstract][Full Text] [Related]
17. Loss of tumor suppressor IGFBP4 drives epigenetic reprogramming in hepatic carcinogenesis.
Lee YY; Mok MT; Kang W; Yang W; Tang W; Wu F; Xu L; Yan M; Yu Z; Lee SD; Tong JHM; Cheung YS; Lai PBS; Yu DY; Wang Q; Wong GLH; Chan AM; Yip KY; To KF; Cheng ASL
Nucleic Acids Res; 2018 Sep; 46(17):8832-8847. PubMed ID: 29992318
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
Huang N; Liao P; Zuo Y; Zhang L; Jiang R
J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
[TBL] [Abstract][Full Text] [Related]
19. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
20. CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping.
Naert T; Tulkens D; Van Nieuwenhuysen T; Przybyl J; Demuynck S; van de Rijn M; Al-Jazrawe M; Alman BA; Coucke PJ; De Leeneer K; Vanhove C; Savvides SN; Creytens D; Vleminckx K
Proc Natl Acad Sci U S A; 2021 Nov; 118(47):. PubMed ID: 34789568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
